ArticleProceedings of the National Academy of Sciences of the United States of America2018
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 55 citations in OpenAlex.
- Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.British journal of cancer · 2019Trial
- Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma.Oncogene · 2025Article
- Multi-Omics Analysis Reveals Immune Infiltration and Clinical Significance of Phosphorylation Modification Enzymes in Lung Adenocarcinoma.International journal of molecular sciences · 2025Article
- Exploring the role of YES1 kinase in regulating cisplatin resistance through iTRAQ-based quantitative proteomic analysis in urothelial carcinoma.American journal of cancer research · 2025Article
- YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.Archives of toxicology · 2024Article
- Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.International journal of molecular sciences · 2024Review
- A renaissance for YES in cancer.Oncogene · 2023Review
- Role of YES1 signaling in tumor therapy resistance.Cancer innovation · 2023Review
- Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase.Investigational new drugs · 2023Article
- Targeting the Src N-terminal regulatory element in cancer.Oncotarget · 2023Article
- Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review.Translational lung cancer research · 2023Review
- Quiescent Cancer Cells-A Potential Therapeutic Target to Overcome Tumor Resistance and Relapse.International journal of molecular sciences · 2023Review
- CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- The Biology and Therapeutic Potential of the Src-YAP Axis in Non-Small Cell Lung Cancer (NSCLC).Cancers · 2022Article
- Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.Nature reviews. Clinical oncology · 2022Review
- SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.JCO precision oncology · 2022Article
- Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.BMC cancer · 2022Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 4 institutions in 1 country.
Pang-Dian FanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065; fanp@mskcc.org varmus@med.cornell.edu ladanyim@mskcc.org.ORCID 0000-0002-7968-7516
Giuseppe NarzisiComputational Biology, New York Genome Center, New York, NY 10013.
Anitha D JayaprakashTechnology Innovation Lab, New York Genome Center, New York, NY 10013.
Elisa VenturiniProject Management, New York Genome Center, New York, NY 10013.
Nicolas RobineComputational Biology, New York Genome Center, New York, NY 10013.
Peter SmibertTechnology Innovation Lab, New York Genome Center, New York, NY 10013.
Soren GermerSequencing Operations, New York Genome Center, New York, NY 10013.
Helena A YuDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Emmet J JordanDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Paul K PaikDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Yelena Y JanjigianDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Jamie E ChaftDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Lu WangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Achim A JungbluthDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Sumit MiddhaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Lee SpraggonDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Huan QiaoVanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232.
Christine M LovlyVanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232.
Mark G KrisDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Gregory J RielyDivision of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Katerina PolitiDepartment of Pathology and the Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520.
Harold VarmusCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065 fanp@mskcc.org varmus@med.cornell.edu ladanyim@mskcc.org.
Marc LadanyiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065; fanp@mskcc.org varmus@med.cornell.edu ladanyim@mskcc.org.
Memorial Sloan Kettering Cancer Center · USNew York Genome Center · USVanderbilt University · USYale Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Ventura · 2007 to 2026
$31.2MYale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Kurt A Schalper · 2015 to 2026
$31.1MVanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MMutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic MiceR01CA120247 · NCI · YALE UNIVERSITY · PI POLITI, KATERINA ABIGAIL · 2006 to 2014
$3.8MOvercoming acquired resistance to EGFR inhibitors in lung cancerR01CA121210 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LOVLY, CHRISTINE M. · 2007 to 2016
$2.9MNCI NIH HHS K12 CA090625NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA196530NCI NIH HHS R01 CA120247NCI NIH HHS R01 CA121210
Abstract
In ∼30% of patients with
Indexed as
DNA Transposable ElementsDrug Resistance, NeoplasmErbB ReceptorsGene AmplificationLung NeoplasmsProto-Oncogene Proteins c-yesCell Line, TumorEnzyme InhibitorsGene Expression Regulation, NeoplasticHumansProto-Oncogene Proteins c-fynProto-Oncogene Proteins pp60(c-src)DNA Transposable ElementsEGFR protein, humanEnzyme InhibitorsErbB ReceptorsFYN protein, humanProto-Oncogene Proteins c-fynProto-Oncogene Proteins c-yesProto-Oncogene Proteins pp60(c-src)YES1 protein, humanacquired resistanceALKEGFRlung adenocarcinomaYES1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.